Increase the competitiveness of the industrial health complex.

Contribute toward the reduction of the National Health Policy vulnerability.

Align the Production Development Policy – PDP with the Health National Policy..


» Strategic Purposes

Incentive the increase, under a competitive manner, of the production of medical equipment, materials, reagents and devices for diagnosis, hemo-derivatives, immunobiological, chemical intermediaries and vegetable extracts for therapeutic purposes, pharmaceutical active principles and medications for human use, as well as corrected products inserted within the industrial health complex;

Contribute towards the international insertion of national companies of the industrial health complex;

Contribute towards the formation and consolidation of an exporting base in the country;

Induce research, development and local production of medical equipment, materials, reagents and devices for diagnosis, hemo-derivatives, immunobiological, chemical intermediaries and vegetable extracts for therapeutic purposes, pharmaceutical active principles and medications for human use, as well as corrected products inserted within the industrial health complex of strategic interest to the National Health Policy;

Stimulate the dissemination of the innovative activity within the industrial health complex;

Contribute towards the improvement of efficiency and efficacy of public producers' actions.  



» Intermediary Purposes

Support investments of companies form the Industrial Health Complex in favor of the construction, expansion and modernization of the productive capacity, as well as in favor of increasing the efficacy of their management and corporate governance;

Support investments of companies from the Industrial Health Complex in favor of the compliance with the requirements of the national regulatory body - ANVISA - National Sanitary Surveillance Agency, as well as compliance with the requirements of international regulatory bodies and of the World Health Organization [WHO];

Support the necessary investments for the internationalization of national companies from the Industrial Health Complex, whether through exports, strategic partnerships or fixed investments abroad;

Support activities that contribute toward the formation and consolidation of a exporting base in the country;

Support under a differentiated manner, the innovative projects of companies from the Industrial Health Complex, in cooperation or not with Technological Scientific Institutions, whether related to radical or incremental innovations;

Support projects that purpose to contribute towards the construction and consolidation of the health innovation infrastructure in the Country;

Support, through partaking in the risk of the undertaking and/or company, specific innovative projects of national companies from the Industrial Health Complex, which bring together traits of a significant technological challenge and priority to the National Health Policy;

Support projects from public producers of reagents and devices for diagnosis, hemo-derivatives, immunobiological, chemical intermediaries and vegetable extracts for therapeutic purposes, pharmaceutical active principles and medications for human use that purpose incremental or radical innovations, compliance with requirements of regulatory bodies and implementation of quality assurance and improvement of governance and management mechanisms, always in congruence with the Department of Health priorities. 



»Concepts Used

Under the ambit of this Program, the following concepts will be adopted:

Research and development activities (R&D): Encompasses the creative work carried out under a systematic manner with the goal to increase the inventory of knowledge and the use of that inventory of knowledge to predict new applications.

External R&D Acquisition: encompasses the activities described in the previous item carried out by other organizations (companies or scientific and technological institutions) and purchased by the Company.

Scientific and Technological Institution [ICT]: public or private non-profit body or entity, which bears in their institutional mission, amongst other things, carry out basic or applied research activities of scientific or technological bearing, including teaching and research entities, among others.

Innovation: implementation of products (goods or services) or technologically new processes or significantly improved under the Brazilian market ambit.

Incremental Innovation: existent product or process which performance has been significantly improved within the Brazilian market ambit.

Radical Innovation: product or process which characteristics, attributes or use differ significantly when compared to already existent products and processes in the Brazilian market. Such innovations may involve radically new technologies or may be based on the combination of existent technologies for new uses. 

Strategic Partnership: production and/or commercialization initiatives amongst national companies associated together or with foreign partner company purposing to promote exportation of goods produced exclusively in Brazil.

Products Inserted on the Industrial Health Complex: medical equipment, materials, reagents and devices for diagnosis, hemo-derivatives, immunobiological, chemical intermediaries and vegetable extracts for therapeutic purposes, pharmaceutical active principles and medications for human use. 


» Effectiveness

07.31.2012